The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer.

Journal: Clinical genitourinary cancer
PMID: 32171601

Abstract

BACKGROUND: Androgen-deprivation therapy is the mainstay of treatment for metastatic prostate cancer. Corticosteroids and estrogens are also useful agents in castration-resistant prostate cancer (CRPC). However, oral estrogens are associated with thromboembolic events, which limits their use, and transdermal estrogens may offer a safer alternative. This study was carried out to determine the safety and effectiveness of transdermal estrogens in CRPC.

Authors

  • Katherine Smith
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
  • Myria Galazi
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
  • Mark R Openshaw
    Department of Medical Oncology, Charing Cross Hospital, Imperial College NHS Trust, London, UK.
  • Peter Wilson
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
  • Shah J Sarker
    Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.
  • Neale O'Brien
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
  • Constantine Alifrangis
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
  • Justin Stebbing
    Department of Surgery and Cancer, Imperial College, London, UK.
  • Jonathan Shamash
    Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK. Electronic address: jonathan.shamash@bartshealth.nhs.uk.

Keywords

External Resources

Popular Topics
Recent Journals